Cerus Corp
CERS
Detailliertes Diagramm anzeigen
1.300USD
+0.070+5.69%
Handelsschluss 09/18, 16:00（ET）Kurse um 15 Minuten verzögert
249.06MMarktkapitalisierung
VerlustKGV TTM
Intraday
1m
30m
1h
D
W
M
D
Heute
+5.69%
5 Tage
+10.17%
1 Monat
+4.84%
6 Monate
-10.34%
Seit Jahresbeginn
-15.58%
1 Jahr
-34.01%
Detailliertes Diagramm anzeigen
TradingKey Aktien-Score
Währung: USD Aktualisiert：2025-09-17Wichtige Einblicke
Die Fundamentaldaten des Unternehmens sind relativ stabil. Seine Bewertung wird als unterbewertet angesehen,und die institutionelle Anerkennung ist sehr hoch. In den letzten 30 Tagen haben mehrere Analysten die Aktie mit einer Kaufen bewertet. Trotz einer schwachen Aktienmarktperformance zeigt das Unternehmen starke Fundamentaldaten und technische Indikatoren. Der Aktienkurs bewegt sich seitwärts zwischen den Unterstützungs- und Widerstandsniveaus, was ihn für schwankungsorientiertes Trading geeignet macht.
Aktienbewertung
Widerstand & Unterstützung
Keine Daten
Radar Chart
Aktueller Preis
Vorher
Analysten-Ziel
Basierend auf insgesamt
4
Analysten
Kaufen
Aktuelles Rating
4.667
Kursziel
+270.37%
Aufwärtspotenzial
Hinweis: Analystenbewertungen und Kursziele werden von LSEG ausschließlich zu Informationszwecken bereitgestellt und stellen keine Anlageberatung dar.
Unternehmens-Highlights
HöhepunkteRisiko
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
valuation_overestimated
valuation_overestimated_desc%!(EXTRA string=PE, string=-12.30)
institutional_decreasing_position
institutional_decreasing_position_desc%!(EXTRA string=150.59M, string=7.25%)
institutional_hold%!(EXTRA string=Catherine Wood)
institutional_hold_desc%!(EXTRA string=Catherine Wood, string=19.21M)
Nachrichten
Bald gibt es mehr Neuigkeiten, bleiben Sie dran...
Finanzindikatoren
EPS
Keine Daten
Gesamteinnahmen
Keine Daten
Unternehmen
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
BörsenkürzelCERS
UnternehmenCerus Corp
CEOMr. William M. (Obi) Greenman
Websitehttps://www.cerus.com/
Verwandte Finanzinstrumente
+0.31%
+0.18%
+1.07%
+0.61%
+0.43%
+2.29%
+0.76%
-0.86%
+0.75%
+3.50%
+0.31%
-0.64%
-0.72%
+4.51%
+0.41%
+2.16%
+0.56%
+2.42%
+1.75%
+1.25%
